Last reviewed · How we verify
NCT04573894
Diagnostic Performance of Plasma Procalcitonin for the Detection of Blood Cultures Contaminations
trial testing Procalcitonin dosage in Blood Culture Contamination in 147 participants. Completed in 5 September 2020.
31 July 2020
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 147 |
| Start date | 1 June 2020 |
| Primary completion | 31 July 2020 |
| Estimated completion | 5 September 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Procalcitonin dosage
Conditions studied
- Blood Culture Contamination — all drugs for Blood Culture Contamination →
- Bacteremia — all drugs for Bacteremia →
- Contamination — all drugs for Contamination →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Blood Culture Contamination or Bacteremia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In blood cultures, species considered as potentially contaminating (coagulase negative staphylococci (CNS), Bacillus spp., Corynebacterium spp., Cutibacterium acnes, Micrococcus spp., viridans group streptococci, and Clostridium perfringens) can, however, be responsable for true bacteremia. Blood levels of the prohormone procalcitonin (PCT) markedly increase in the early stages of bacterial infections. The aim of our study is to determine the role of plasma PCT as a biomarker differentiating blood culture contaminations from true bacteremia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Accuracy of procalcitonin for diagnosing peripheral blood culture contamination among patients with positive blood culture for potential contaminants.
Berthezène C, Aissa N, Manteaux AE, Guéant JL, et al · · 2021 · cited 5× · PMID 34524647 · DOI 10.1007/s15010-021-01697-4
Verify or expand the search:
- PubMed search for NCT04573894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Blood Culture Contamination
Currently open trials in the same condition.
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04573894 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing